Evidence map›Paper›PMID 42192286›Full record

ArticleMolecular medicine (Cambridge, Mass.)2026

Machine learning, whole genome sequencing, and Mendelian randomization support a role of CRP on COVID-19 severity.

Francesca Lantieri, Stefania Croci, Sergio Decherchi, Marta Rusmini, Giada Recchi, Martina Bonacini, Ilaria Ferrigno, Alessandro Rossi, Yeraldin Chiquinquira Castillo De Spelorzi, Edoardo Henzen and 16 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Francesca Lantieri *Biostatistics Unit, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Stefania Croci *Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Sergio Decherchi *Fondazione Istituto Italiano di Tecnologia, Genoa, Italy.
Marta RusminiClinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Giada RecchiRheumatology and Autoinflammatory Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Martina BonaciniUnit of Clinical Immunology, Allergy and Advanced Biotechnologies, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Ilaria FerrignoUnit of Clinical Immunology, Allergy and Advanced Biotechnologies, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Alessandro RossiUnit of Clinical Immunology, Allergy and Advanced Biotechnologies, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Yeraldin Chiquinquira Castillo De SpelorziGenomics Facility, Fondazione Istituto Italiano di Tecnologia, Genoa, Italy.
Edoardo HenzenGenomics Facility, Fondazione Istituto Italiano di Tecnologia, Genoa, Italy.
Francesca RosamiliaClinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Davide CangelosiClinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Fabio LanduzziComputational Genomics, Center for Clinical and Computational Genomics (C3G), Italian Institute of Technology, Aosta, 11100 , Italy.
Andrea AngiusInstitute of Genetics and Biomedical Research, National Research Council, University Campus of Cagliari, Monserrato, Cagliari, Italy.
Vincenzo RalloInstitute of Genetics and Biomedical Research, National Research Council, University Campus of Cagliari, Monserrato, Cagliari, Italy.
Pamela MancusoUnit of Epidemiology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Annamaria PezzarossiUnit of Epidemiology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Paolo Giorgi RossiUnit of Epidemiology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Mariagrazia CatanosoUnit of Rheumatology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Marco GattornoRheumatology and Autoinflammatory Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Andrea CavalliComputational and Chemical Biology, Fondazione Istituto Italiano di Tecnologia, Genoa, Italy.
Pier Luigi MeroniLaboratory of Immunorheumatologic Researches, IRCCS Istituto Auxologico Italiano, Milan, Italy.
Diego VozziGenomics Facility, Fondazione Istituto Italiano di Tecnologia, Genoa, Italy.
Paolo UvaClinical Bioinformatics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Isabella CeccheriniUOSD Research Laboratories Aggregation Area, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini, Genoa, 5 - 16147, Italy. isabellaceccherini@gaslini.org.
Carlo SalvaraniUnit of Rheumatology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Funding

Foundation for Research in Rheumatology research grant 053/2020 to IC, AC, PLM, CSMinistero della Salute "5x1000" and "Ricerca Corrente" to Giannina Gaslini InstituteMinistero della Salute "Ricerca sul Covid-19" COVID-2020-12371808 to CS and PLM
6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019 (COVID-19) ranges from asymptomatic to very severe infection and death, largely depending on host factors, including genetics. We have investigated clinical and genetic data from 200 COVID-19 patients to search for factors predisposing to increased disease severity.

methodsPatients were divided into non-hospitalized mild/pauci-symptomatic and hospitalized severe. An interpretable Machine Learning approach was applied to blood biomarkers while genome-wide associations were performed for COVID-19 severity. Finally, a possible causal role of chronic low-grade inflammation on COVID-19 severity was searched by Mendelian Randomization.

resultsA high severity predictive role was observed in our sample by Machine Learning for the C-Reactive Protein measured in the course of SARS-CoV-2 infection (iCRP). This was also suggested by evidence of association with variants known to be involved in the CRP levels in the general population (pCRP). Finally, a possible causal role of chronic low-grade inflammation on COVID-19 severity could be shown by Mendelian Randomization using publicly available summary statistics of two COVID-19 Genome-Wide Association Studies.

conclusionsConsistent with previous results, a predictive role of CRP levels on COVID-19 severity was detected in our sample. Furthermore, Mendelian Randomization supported a causal role of genetically predicted chronic CRP levels.

Indexed as

COVID-19C-Reactive ProteinMachine LearningBiomarkersFemaleGenome-Wide Association StudyHumansInflammationMaleMendelian Randomization AnalysisMiddle AgedPandemicsSARS-CoV-2Severity of Illness IndexWhole Genome SequencingBiomarkersC-Reactive ProteinCOVID-19 severity predictionC-Reactive ProteinCRP causal roleInterpretable Machine LearningMendelian RandomizationTFEB

Identifiers

PMID42192286
PMCPMC13393844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.